Chronic Myeloid Leukemia: Mechanisms of Resistance and Treatment

Elias Jabbour, Sameer A. Parikh, Hagop Kantarjian, Jorge Cortes

Research output: Contribution to journalReview articlepeer-review

30 Scopus citations


Imatinib mesylate has revolutionized the treatment landscape for patients with newly diagnosed chronic myeloid leukemia. Follow-up has shown excellent response rates, progression-free survival, and overall survival after 8 years. However, some patients develop resistance to imatinib treatment because of a multitude of reasons. Strategies to overcome resistance include dose escalation of imatinib or switching to a second-generation tyrosine kinase inhibitor or to one of the newer non-tyrosine kinase inhibitors. This article guides the treating physician with a rational approach in the management of patients with chronic myeloid leukemia who fail initial treatment with imatinib or lose response while on therapy with imatinib.

Original languageEnglish (US)
Pages (from-to)981-995
Number of pages15
JournalHematology/Oncology Clinics of North America
Issue number5
StatePublished - Oct 2011


  • Homoharringtonine
  • Multikinase inhibitors
  • Mutation screening
  • Myeloproliferative disorders
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Chronic Myeloid Leukemia: Mechanisms of Resistance and Treatment'. Together they form a unique fingerprint.

Cite this